Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
XXB-750 by Novartis for Systolic Heart Failure: Likelihood of Approval
XXB-750 is under clinical development by Novartis and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase...
XXB-750 by Novartis for Resistant Hypertension: Likelihood of Approval
XXB-750 is under clinical development by Novartis and currently in Phase II for Resistant Hypertension. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Novartis's XXB-750?
XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure. According to...